ExpreS²ion Biotech Holding AB (“ExpreS²ion “) announces that the Company has met the requirements for listing on Nasdaq Stockholm First North and today, July 27, it has received the stock exhange’s formal approval. The first day of trading of ExpreS²ion’s shares is expected to be July 29, 2016.

CEO Steen Klysner comments

“In June we carried out a successful Initial Public Offering (IPO), which reflected the interest there is in ExpreS²ion. With the proceeds from the IPO, we can now continue to expand our marketing and sales efforts to enable a larger market penetration for our ExpreS² platform.”

Company description available

ExpreS²ions company description is available via the following link: http://expres2ionbio.com/files/bolagsbeskrivning.pdf

Read the whole press release (pdf)